ois seco header mobile


Todd Brady, MD, PhD, CEO - Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our pre-commercial product candidates are reproxalap, a potential treatment for dry eye disease and allergic conjunctivitis, and ADX-2191, a potential treatment for primary vitreoretinal lymphoma, proliferative vitreoretinopathy, and retinitis pigmentosa. In addition, we are developing other product candidates, including ADX-629 and chemically related molecules, for the potential treatment of systemic and retinal immune-mediated diseases.

Marc Gleeson, CEO - Azura Ophthalmics

At Azura Ophthalmics, we are utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions. Our goal is to change the paradigm for the treatment of ophthalmic conditions by delivering First-in-Class Ophthalmic Keratolytics by harnessing the power of keratolytics for lid margin and ocular surface diseases. 

Jay Cormier, President & CEO - Eyedaptic

Eyedaptic’s unique software, embedded in Augmented Reality glasses, helps those with retina-related vision loss, such as AMD, improve their quality of life. Our proprietary simulated natural vision software is adaptive to the user’s vision, environment and habits with machine learning. 

Barry Linder, MD, President & CEO - Eyedetec Medical

Dry Eye Disease (DED) significantly impacts quality of life and vision, and the incidence is growing 9.2% annually. The aging population, contact lens use, corneal surgery, and time spent on digital screens all contribute to the increasing incidence. There is currently no cure, and available treatments are often painful, costly, and create significant anxiety for the patient. Eyedetec Medical understands the DED market through its commercially available, Class I product (EyeGiene®) for treatment of mild DED.

Eyedetec will introduce its 2nd product in 2023. The novel, next-generation device is intended to treat moderate to severe DED patients. The product has proven to be effective clinically, is comfortable, affordable, and highly relaxing. The unique business model includes fitting the device in the doctor’s office for an initial treatment, and then patients take the device home where therapy is continued. The scalability and flexibility of this approach enables doctors to meet growing patient demand while generating meaningful new revenue. The device incorporates 3 mechanisms in an entirely novel manner. This next-generation therapy is easier to use, more comfortable for the patient, and significantly less expensive than alternatives. Clinical data is compelling.

Chris Adams, CEO - Glint Pharmaceuticals

Glint Pharmaceuticals is commercializing a patented nano barrier technology to treat eye diseases, from glaucoma to corneal surface abnormalities, from ocular surgery to trauma. The technology incorporates a drug delivery mechanism into a commercially available, single use disposable contact lens. The Glint lens provides a new, non-surgical method to treat eye disease, increasing patient compliance while delivering single or multiple drugs to the eye. 


The Glint technology is a novel, nano barrier patented approach for extended drug delivery by the incorporation of vitamin E (α tocopherol) in commercial silicone hydrogel contact lenses. The Glint approach has a competitive advantage over other ocular drug delivery products. The technology uses commercial lenses, is easily scalable and can deliver multiple drugs separately or in combination. The drug eluding Glint contact lenses maintain transparency, wettability, UV-blocking capability, as well as oxygen and ion permeability. Multiple drugs can be programmed to be released from a single disposable contact lens. 


The company has an approved IND for 1. Treatment of glaucoma by combination therapy of timolol and dorzolamide, and 2. Treatment of corneal infections by antibiotic (moxifloxacin). The company has initial clinical data for both lenses and additional clinical studies are ongoing. 

Dhaval Desai, SVP & Chief Development Officer - Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration.

Marc Odrich, MD, Chief Medical Officer - LENZ Therapeutics

LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Its lead programs, LNZ100 and LNZ101, are aceclidine-based eye drops designed to restore the loss of near vision associated with presbyopia. Aceclidine is the only miotic shown to achieve a sub-2mm pupil without overstimulating the ciliary muscle. 

MaryAnn Klassner, Founder & President - Meivertor

The Only single-handed Upper and lower eyelid eversion tool, designed specifically to simplify the everyday task of taking images of meibomian glands, foreign body removal and assessment of contact lens tolerance. 

Mackenzie Andrews, Chief Commercial Officer - Nanodropper

Nanodropper is a medical device company offering high-value solutions to adherence barriers in eye disease management. Nanodropper Adaptor, the flagship product, is an eyedrop bottle adaptor that solves the problem of oversized eyedrops. Our award-winning device reduces eyedrops to the physiologically appropriate volume, reducing financial barriers and improving access to vision-saving medications. Nanodropper adds value at every level in healthcare, with the potential to save billions of dollars in medication waste, one drop at a time. 

Christian Roesky, PhD, CEO & Managing Director - Novaliq

Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. 

EyeSol® is Novaliq’s proprietary technology using pharmaceutical pure semifluorinated alkanes (SFAs). SFAs are physically, chemically, and physiologically inert, have an excellent biocompatibility and a very good safety profile. Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. The company has recently announced filing New Drug Applications (“NDA”) to the Food and Drug Administration (“FDA”) for their investigational dry eye disease drug therapies, NOV03 (licensed to B&L) and CyclASol®. 

Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies.

Keith Ignotz
Ocumedic 500200

Keith Ignotz, President & CEO - OcuMedic

Controlled Drug Delivery via a Contact Lens 

OcuMedic has developed a novel, non-invasive, and patented contact lens drug delivery platform, able to provide time released delivery of a large array of prescription and OTC eye drops and comfort agents. OcuMedic has overcome the technical hurdles concerning clarity, oxygen diffusivity, stiffness, hydration and thickness that have blocked previous attempts to create a drug delivery contact lens.   

The Company’s initial product, Freedom™ Bandage Lens, a Bromfenec based ”First Line” non-steroidal treatment for pain and inflammation to be used for the indications of post cataract and LASIK surgeries, cornea abrasion and non-infectious Uveitis, collectively representing nearly 35 million procedures per year. The Company has held its pre-IND meeting with the FDA this year and has a clearly defined clinical 505(b)(2) pathway for development with only limited animal dose ranging studies needed before entering the clinic. 


Mina Sooch, MBA, CEO - Ocuphire Pharma

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.Our pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

Nyxol® Eye Drops
Nyxol is being developed for several indications including pharmacologically-induced mydriasis, presbyopia, and dim light or night vision disturbances.

Nyxol is an investigational 505(b)(2) product candidate that has been studied in over 650 subjects across 12 completed Phase 1, 2, and 3 trials.

Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

APX3330 has been studied in over 340 patients across six Phase 1 and five Phase 2 trials.

David Tanzer, MD, CMO - OcuTerra Therapeutics

OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the progression of disease. Our initial therapeutic, OTT166, administered as an eye drop containing a novel integrin-inhibitor, is in Phase 2 clinical development to enable earlier, non-invasive, active treatment of non-proliferative diabetic retinopathy (NPDR), a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to clinicians and their patients who are consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. 

Paul Smith, President & COO - Orasis Pharmaceuticals

Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company that is preparing to commercialize CSF-1 for the treatment of presbyopia as an alternative to reading glasses. CSF-1 is a proprietary formulation of preservative-free, low-dose pilocarpine, 0.4%, along with a multi-faceted vehicle which was designed with the patient in mind. Orasis is led by a collaborative team of industry executives and clinicians focused on reshaping vision possibilities. Orasis has offices in both the US and Israel.

Ralf Hornig, MD, Director of Clinical Affairs - Pixium Vision


To create a world of bionic vision for those who have lost their sight. 


To provide best in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living. 

Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. 

Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene. 

For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system. 

Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date. 

YoungMin Huh, PhD, Data Science Leader - S-Alpha Therapeutics

S-Alpha therapeutics, Inc is company which is dedicating to develop Software as medical device for overcoming children myopia(SAT-001). 

Patrick Johnson, PhD, President - Sydnexis

Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD-101, in a Phase 3 clinical trial to decrease myopia progression in children.

Aziz Mottiwala, Chief Commercial Officer - Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis. This highly prevalent eyelid margin disease affects approximately 25 million eye care patients in the U.S., with no FDA-approved treatments currently available. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus’ second candidate, TP-05, is an oral, non-vaccine therapeutic under investigation for the prevention of Lyme disease and is being studied in a Phase 1b clinical trial. Learn more at TarsusRx.com.

Monty Montoya, CEO - TherOptix

Our mission is to revolutionize ophthalmic drug delivery using a proprietary novel drug-eluting
contact lens platform providing more effective, sustained, and safer therapies for patients. With strong IP developed at MIT/Mass Eye & Ear/Boston Children's Hospital, we are focused on post-surgical pharmaceutical needs in ophthalmology with two drug-eluting lenses currently in development: TetraLens and DexaLens.

Benjamin Sullivan, MD, Chief Scientific Officer - Trukera Medical

TearLab Is Now Trukera Medical. TearLab, founded in 2009, was built upon the recognition of the importance of corneal health to eye care practices. We introduced tear osmolarity testing to eye care with our flagship device, the TearLab Osmolarity System, which has been used to perform over 24 million tests worldwide. In 2022, we announced a corporate name change to Trukera Medical, for our further expansion in corneal health. What began with a focus on osmolarity testing is now a comprehensive corneal health company working to address additional unmet medical needs in eye care. As Trukera Medical, it is our vision to be the world’s leading and most trusted corneal health company for providers and patients.

Robert Sambursky, MD, President - Verséa

Verséa™ Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies on a mission to revolutionize eye care. It is specialized in the sale and distribution of innovative solutions for the diagnosis, treatment, and management of ocular surface diseases. To learn more, visit Verséa™ Ophthalmics webpage

The new diagnostic platform is a result of an exclusive global commercial partnership with AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases.

Jeffrey Nau, PhD, President of the Eye Care Division - Viatris

Oyster Point Pharma, Inc. is now a part of Viatris. Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®.  Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. 

Alberto Osio, President & CEO - Yolia Health

Yolia Health has developed the 1 st non-invasive and repeatable platform of treatments for vision problems such as myopia, presbyopia, hyperopia and post-surgical (LASIK and cataract) patients. 

Yolia’s True Vision Treatment (TVT) requires patients to use patented customized contact lenses and ophthalmic eye drops for only three days. TVT results last for 12 months on average and can be repeated as needed. TVT is approved in Mexico and has recently been designated to CDRH (device) by the FDA. Estimated time for US approval by 2025. 

Yolia Health is a Delaware Corporation founded in 2006 with more than 54 international patents and many more pending.